(Q33885871)

29 July 2017

1 reference

title

New pharmacodynamic parameters for antimicrobial agents (English)

1 reference

29 July 2017

1 reference

Li RC

1

1 reference

29 July 2017

1 February 2000

1 reference

International Journal of Antimicrobial Agents

29 July 2017

1 reference

29 July 2017

13

1 reference

29 July 2017

4

1 reference

29 July 2017

229-235

1 reference

Pharmacodynamic modeling of bacterial kinetics: beta-lactam antibiotics against Escherichia coli.

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900114-4

7 January 2021

Simultaneous pharmacodynamic analysis of the lag and bactericidal phases exhibited by beta-lactams against Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900114-4

7 January 2021

Kinetic analysis and characterization of the bacterial regrowth after treatment of Escherichia coli with beta-lactam antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900114-4

7 January 2021

Microbial kinetics of beta-lactam antibiotics against Escherichia coli.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900114-4

7 January 2021

Mechanistic investigation of the reduction in antimicrobial activity of ciprofloxacin by metal cations.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900114-4

7 January 2021

The fractional maximal effect method: a new way to characterize the effect of antibiotic combinations and other nonlinear pharmacodynamic interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900114-4

7 January 2021

Performance of the fractional maximal effect method: comparative interaction studies of ciprofloxacin and protein synthesis inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900114-4

7 January 2021

The pharmacodynamics of aminoglycosides

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900114-4

7 January 2021

Prospective randomized study of once-daily versus thrice-daily netilmicin regimens in patients with intraabdominal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900114-4

7 January 2021

Postantibiotic leukocyte enhancement: increased susceptibility of bacteria pretreated with antibiotics to activity of leukocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900114-4

7 January 2021

Impact of pharmacokinetics on the postantibiotic effect exhibited by Pseudomonas aeruginosa following tobramycin exposure: application of an in-vitro model

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900114-4

7 January 2021

Correlation between bactericidal activity and postantibiotic effect for five antibiotics with different mechanisms of action.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900114-4

7 January 2021

Influence of protein binding on therapeutic efficacy of cefoperazone

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900114-4

7 January 2021

New In Vitro Model to Study the Effect of Antibiotic Concentration and Rate of Elimination on Antibacterial Activity

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900114-4

7 January 2021

Bactericidal Activity of Cephalosporins in an In Vitro Model Simulating Serum Levels

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900114-4

7 January 2021

An in vitro model for monitoring bacterial responses to antibiotic agents under simulated in vivo conditions

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900114-4

7 January 2021

Historical review of in-vitro models

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900114-4

7 January 2021

Advantages and disadvantages of an in-vitro model with two compartments connected by a dialyser: results of experiments with ciprofloxacin.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900114-4

7 January 2021

Two compartment kinetic model with multiple artificial capillary units

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900114-4

7 January 2021

In-vitro model for simultaneous simulation of the serum kinetics of two drugs with different half-lives.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900114-4

7 January 2021

Simultaneous simulation of two different concentration time curves in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900114-4

7 January 2021

Effect of antibiotics eliminated by first order kinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900114-4

7 January 2021

Evaluation of activity of temafloxacin against Bacteroides fragilis by an in vitro pharmacodynamic system

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900114-4

7 January 2021

Differences between bacteria grown in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900114-4

7 January 2021

Application of in-vitro models: development of resistance.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900114-4

7 January 2021

Pharmacokinetic-pharmacodynamic modeling of the antibiotic effect of piperacillin in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900114-4

7 January 2021

Twenty-four-hour area under the concentration-time curve/MIC ratio as a generic predictor of fluoroquinolone antimicrobial effect by using three strains of Pseudomonas aeruginosa and an in vitro pharmacodynamic model

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900114-4

7 January 2021

Experimental efficacy of combined ceftriaxone and amoxycillin on penicillin-resistant and broad-spectrum cephalosporin-resistant Streptococcus pneumoniae infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900114-4

7 January 2021

Microbial pharmacodynamics of piperacillin in neutropenic mice of systematic infection due to Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900114-4

7 January 2021

Comparative activities of piperacillin, ceftazidime, and amikacin, alone and in all possible combinations, against experimental Pseudomonas aeruginosa infections in neutropenic rats

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900114-4

7 January 2021

Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900114-4

7 January 2021

Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900114-4

7 January 2021

Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900114-4

7 January 2021

Antibiotic kinetics and dynamics for the clinician.

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900114-4

7 January 2021

The importance of pharmacokinetic/pharmacodynamic surrogate markers to outcome. Focus on antibacterial agents

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900114-4

7 January 2021

Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900114-4

7 January 2021

AUIC--the universal parameter within the constraint of a reasonable dosing interval

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900114-4

7 January 2021

Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900114-4

7 January 2021

Antimicrobial Resistance in Hospital Organisms and Its Relation to Antibiotic Use

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900114-4

7 January 2021

Markedly different rates and resistance profiles exhibited by seven commonly used and newer beta-lactams on the selection of resistant variants of Enterobacter cloacae

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900114-4

7 January 2021

The ability of beta-lactam antibiotics to select mutants with derepressed beta-lactamase synthesis from Citrobacter freundii

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900114-4

7 January 2021

Pharmacodynamic evaluation of factors associated with the development of bacterial resistance in acutely ill patients during therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0924-8579%2899%2900114-4

7 January 2021

10.1016/S0924-8579(99)00114-4

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10755236